Genocea to Present at Upcoming Investor Conferences
January 05, 2022 17:46 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior...
Genocea Biosciences Provides Corporate Update
January 04, 2022 07:00 ET
|
Genocea Biosciences, Inc.
Enters into Inhibigen™ R&D collaboration and option agreement with Janssen Reports progress on the GEN-011 TiTAN™ trial CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences,...
Genocea to Present at the Stifel 2021 Virtual Healthcare Conference
November 10, 2021 19:26 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea Provides Third Quarter 2021 Corporate Update
October 28, 2021 07:00 ET
|
Genocea Biosciences, Inc.
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues Strong presence at the SITC 36th Annual Meeting Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., Oct. ...
Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast
October 21, 2021 16:30 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its third...
Genocea to Present at Upcoming Conferences
September 28, 2021 16:30 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that...
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors
September 13, 2021 16:52 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea to Present at Upcoming Scientific and Investor Conferences
September 07, 2021 19:40 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that...
Genocea Provides Second Quarter 2021 Corporate Update
July 29, 2021 07:00 ET
|
Genocea Biosciences, Inc.
GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GEN-009 neoantigen vaccine candidate shows promising long-term clinical results Conference call today at 8:30 a.m....
Genocea to Host Second Quarter 2021 Corporate Update Conference Call & Webcast
July 22, 2021 17:05 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation cancer immunotherapies, will host its second...